Discovery of Novel Jak2-Stat Pathway Inhibitors with Extended Residence Time on Target.
Guan, H., Lamb, M.L., Peng, B., Huang, S., Degrace, N., Read, J., Hussain, S., Wu, J., Rivard, C., Alimzhanov, M., Bebernitz, G., Bell, K., Ye, M., Zinda, M., Ioannidis, S.(2013) Bioorg Med Chem Lett 23: 3105
- PubMed: 23562594 
- DOI: 10.1016/j.bmcl.2013.02.111
- Primary Citation of Related Structures:  
3ZMM - PubMed Abstract: 
The discovery of the activating mutation V617F in the JH2 domain of Jak2 and the modulation of oncogenic Stat3 by Jak2 inhibitors have spurred a great interest in the inhibition of the Jak2/Stat pathway in oncology. In this Letter, we communicate the discovery of novel inhibitors of the Jak2/Stat5 axis, the N-(1H-pyrazol-3-yl)pyrimidin-2-amino derivatives ...